Abstract
The production and action of primary proinflammatory cytokines are strictly controlled by a series of circuits to avoid damage that they can cause if produced in excess. Interleukin-10 and interleukin-1 receptor antagonist contribute to the control of the magnitude of the inflammatory responses in vivo. Benzydamine, a non-steroidal anti-inflammatory drug that has been shown to have suppressive activity for the proinflammatory cytokines, tumor necrosis factor-α and interleukin-1β, was investigated for its effects on interleukin-10 and interleukin-1ra production. The drug did not modify the production of interleukin-10 and interleukin-1ra by peripheral blood mononuclear cells stimulated with lipopolysaccharide, under conditions where tumor necrosis factor-α and interleukin-1β were decreased. The antiinflammatory capacity of benzydamine might thus result from its ability to reduce the production of proinflammatory cytokines, without affecting antiinflammatory factors.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993; 54:167.
Mosmann TR. Properties and functions of interleukin-10. Adv Immunol 1994; 56:1.
Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147:3815.
Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151:1224.
Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348:550.
Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993; 177:1205.
Ferguson TA, Dube P, Griffith TS. Regulation of contact hypersensitivity by interleukin 10. J Exp Med 1994; 179:1597.
Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75:263.
Verdi CJ. Cancer therapy and oral mucositis. An appraisal of drug prophylaxis. Drug Saf 1999; 9:185.
Sironi M, Pozzi P, Polentarutti N, Benigni F, Coletta I, Guglielmotti A, Milanese C, Ghezzi P, Vecchi A, Pinza M, Mantovani A. Inhibition of inflammatory cytokine production and protection against endotoxin toxicity by benzydamine. Cytokine 1996; 8:710.
Sironi M, Milanese C, Vecchi A, Polenzani L, Guglielmotti A, Coletta I, Landolfi C, Soldo L, Mantovani A, Pinza M. Benzydamine inhibits the release of tumor necrosis factor-a and monocyte chemotactic protein-1 byCandida albicans-stimulated human peripheral blood cells. Int J Clin Lab Res 1997; 27:118.
Guglielmotti A, Aquilini L, Rosignoli MT, Landolfi C, Soldo L, Coletta I, Pinza M. Benzydamine protection in a mouse model of endotoxemia. Inflamm Res 1997; 46:332.
Mantovani A, Dinarello C, Ghezzi P. Pharmacology of cytokines. Oxford: Oxford University Press, In press.
Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372:739.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sironi, M., Massimiliano, L., Transidico, P. et al. Differential effect of benzydamine on pro- versus anti-inflammatory cytokine production: lack of inhibition of interleukin-10 and interleukin-1 receptor antagonist. Int J Clin Lab Res 30, 17–19 (2000). https://doi.org/10.1007/s005990070028
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s005990070028